View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Sep. 30, 2016	Nov. 08, 2016
Document Information [Line Items]
Entity Registrant Name	Aviragen Therapeutics, Inc.
Entity Central Index Key	0000072444
Trading Symbol	avir
Current Fiscal Year End Date	--06-30
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		38,640,487
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Millions	Sep. 30, 2016	Jun. 30, 2016
BARDA [Member]
Current assets:
Accounts receivable, net of allowance	$ 0.6	$ 0.7
Cash and cash equivalents	45.9	49.7
Short-term investments	12.4	19.3
Prepaid and other current assets	3.9	2.7
Total current assets	62.8	72.4
Non-current assets:
Property and equipment, net	0.3	0.3
Total assets	63.1	72.7
Current liabilities:
Accounts payable	1.6	3.9
Accrued expenses	5.6	3.6
Short-term note payable	0.4	0.4
Liability related to sale of future royalties, current portion	1.2	1.3
Total current liabilities	8.8	9.2
Non-current liabilities:
Long-term note payable, net of current portion	0.3	0.3
Liability related to sale of future royalties, net of current portion	17.2	16.8
Other long-term liabilities, net of current portion	0.2	0.2
Total liabilities	26.5	26.5
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.10 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.10 par value: 200,000,000 shares authorized; 38,640,487 shares issued and outstanding at September 30, 2016 and June 30, 2016	3.9	3.9
Additional paid-in capital	158.0	157.6
Accumulated other comprehensive income	19.0	19.0
Accumulated deficit	(144.3)	(134.3)
Total stockholders’ equity	36.6	46.2
Total liabilities and stockholders’ equity	$ 63.1	$ 72.7

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2016	Jun. 30, 2016
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	38,640,487	38,640,487
Common stock, shares outstanding (in shares)	38,640,487	38,640,487

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Royalty revenue and milestones	$ 0.1	$ 1.7
Total revenue	0.1	1.7
Operating expense:
Research and development	7.6	5.5
General and administrative	2.2	2.2
Foreign exchange (gain) loss	(0.1)	0.7
Total operating expense	9.7	8.4
Loss from operations	(9.6)	(6.7)
Other (expense) income:
Non-cash interest expense on liability related to sale of future royalties	(0.4)
Interest income		0.1
Total other (expense) income	(0.4)	0.1
Net loss	$ (10.0)	$ (6.6)
Basic net loss per share (in dollars per share)	$ (0.26)	$ (0.17)
Diluted net loss per share (in dollars per share)	$ (0.26)	$ (0.17)
Basic weighted-average shares outstanding (in shares)	38,640,487	38,624,227
Diluted weighted-average shares outstanding (in shares)	38,640,487	38,624,227

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 3 months ended Sep. 30, 2016 - USD ($) $ in Millions	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Jun. 30, 2016	38,640,487				38,640,487
Balances at Jun. 30, 2016	$ 3.9	$ 157.6	$ (134.3)	$ 19.0	$ 46.2
Net loss			(10.0)		(10.0)
Share-based compensation		0.4			$ 0.4
Balances (in shares) at Sep. 30, 2016	38,640,487				38,640,487
Balances at Sep. 30, 2016	$ 3.9	$ 158.0	$ (144.3)	$ 19.0	$ 36.6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (10.0)	$ (6.6)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Share-based compensation	0.4	0.6
Non-cash interest expense related to sale of future royalties	0.4
Change in operating assets and liabilities:
Accounts receivables		9.4
Prepaid expenses and other current assets	(1.2)	(0.2)
Accounts payable and accrued expenses	(0.3)	(2.3)
Net cash (used in) provided by operating activities	(10.7)	0.9
Cash flows from investing activities:
Purchases of short and long-term investments		(1.2)
Maturity of short-term investments	6.9	1.0
Net cash provided by (used in) investing activities	6.9	(0.2)
Cash flows from financing activities:
Payment on note payable		(0.1)
Net cash used in financing activities		(0.1)
(Decrease) increase in cash and cash equivalents	(3.8)	0.6
Cash and cash equivalents at beginning of period	49.7	44.7
Cash and cash equivalents at end of period	$ 45.9	$ 45.3

Note 1 - Company Overview

3 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Nature of Operations [Text Block]

(1)	Company Overview

Aviragen Therapeutics, Inc., together with its wholly owned subsidiaries (“Aviragen”, or the “Company”) is a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus (“HRV”) upper respiratory infections in moderate and severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 2 development for the treatment and prevention of respiratory syncytial virus (“RSV”) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 and 11. The Company is incorporated in the state of Delaware and its corporate headquarters are located in Alpharetta, Georgia.

Although several of the Company’s influenza product candidates have been successfully developed and commercialized to-date by other larger pharmaceutical companies under collaboration, license or commercialization agreements with the Company, it has not independently developed or received regulatory approval for any product candidate, and the Company does not currently have any sales, marketing or commercial capabilities. Therefore, it is possible that the Company may not successfully derive any significant product revenues from any product candidates that it is developing now, or may develop in the future. The Company expects to incur losses for the foreseeable future as it intends to support the clinical and preclinical development of its product candidates.

The Company plans to continue to finance its operations with (i) existing cash, cash equivalents and investments, (ii) proceeds from existing or potential future royalty-bearing licenses or collaborative research and development arrangements, (iii) future equity and/or asset or debt financings, or (iv) other financing arrangements. The Company’s ability to continue to support its operations is dependent, in the near-term, upon managing its cash resources, continuing to receive royalty revenue under existing licenses, entering into future collaboration, license or commercialization agreements, the successful development of its product candidates, executing future financings and ultimately, upon the approval of its products for sale and achieving positive cash flows from operations on a consistent basis. There can be no assurance that additional capital or funds will be available on terms acceptable to the Company, if at all, that the Company will be able to enter into collaboration, license or commercialization agreements in the future, or that the Company will ever generate significant product revenue and become operationally profitable on a consistent basis.

Note 2 - Basis of Presentation

3 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

(2)	Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. All material adjustments considered necessary for a fair presentation have been included. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). Except as disclosed herein, there has been no material change in the information disclosed in the notes to the condensed consolidated financial statements included in the Company’s Annual Report on Form 10-K that was filed with the SEC on September 13, 2016.

The unaudited interim condensed consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All inter-company transactions and balances are eliminated in consolidation.

Operating results for the three months ended September 30, 2016 are not necessarily indicative of those in future quarters or the annual results that may be expected for the Company’s fiscal year ending June 30, 2017. For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the fiscal year ended June 30, 2016 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on September 13, 2016.

The Company’s significant accounting policies have not changed since June 30, 2016.

Recent Accounting Standards

In May 2014, the FASB issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2017. Accordingly, the Company will adopt this guidance on July 1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements.

In August 2014, the FASB issued authoritative accounting guidance related to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. This guidance is effective for annual reporting ending after December 15, 2016, and for annual periods and interim periods thereafter with early application permitted. Accordingly, the standard is effective for the Company on June 30, 2017. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

In January 2016, the FASB issued guidance related to financial instruments - overall recognition and measurement of financial assets and financial liabilities. The guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for public companies for interim and annual periods beginning after December 15, 2017. Accordingly, the standard is effective for the Company on July 1, 2018. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements.

In February 2016, the FASB issued new guidance on leases. This guidance replaces the prior lease accounting guidance in its entirety. The underlying principle of the new standard is the recognition of lease assets and lease liabilities by lessees for substantially all leases, with an exception for leases with terms of less than twelve months. The standard also requires additional quantitative and qualitative disclosures. The guidance is effective for interim and annual reporting periods beginning after December 15, 2018, and early adoption is permitted. The standard requires a modified retrospective approach, which includes several optional practical expedients. Accordingly, the standard is effective for the Company on July 1, 2019. The Company is currently evaluating the impact that this guidance will have on the consolidated financial statements.

Note 3 - Fair Value Measurements

3 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Fair Value Disclosures [Text Block]

(3)	Fair Value Measurements

A fair value hierarchy has been established that requires the Company to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The fair value hierarchy describes three levels of inputs that may be used to measure fair value:

	Level 1	Quoted prices in active markets for identical assets or liabilities.

	Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table sets forth the financial assets and liabilities that were measured at fair value on a recurring basis at September 30, 2016 and June 30, 2016, by level within the fair value hierarchy. The assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

A portion of the Company’s short-term investments have been classified as Level 2, which have been initially valued at the transaction price and subsequently revalued, at the end of each reporting period, utilizing a third party pricing service. The pricing service utilizes industry standard valuation models and observable market inputs to determine value that include surveying the bond dealer community, obtaining benchmark quotes, incorporating relevant trade data, and updating spreads daily. There have been no transfers of assets or liabilities between the fair value measurement classifications.

(in millions)			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
September 30 , 201 6	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	9.4	$	9.4	$	—	$	—
Short-term investments available-for-sale		12.4		6.0		6.4		—
Total	$	21.8	$	15.4	$	6.4	$	—

(in millions)			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
June 30, 201 6	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	1.5	$	1.5	$	—	$	—
Short-term investments available-for-sale	19.3			10.0		9.3		—
Total	$	20.8	$	11.5	$	9.3	$	—

Cash equivalents consist primarily of money market funds. Short-term investments consist of U.S. agency securities, certificates of deposit, corporate securities and U.S. Treasury securities, classified as available-for-sale and have maturities greater than 365 days from the date of acquisition.

The following table shows the unrealized gains and losses and fair values for those investments as of

September 30, 2016 and June 30, 2016 aggregated by major security type:

(in millions)			Unrealized		Unrealized
September 30, 2016	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	9.4	$	—	$	—	$	9.4
Debt securities of U.S. government agencies		2.0		—		—		2.0
U.S. Treasury securities		4.0		—		—		4.0
Corporate notes		2.0		—		—		2.0
Certificates of deposit		4.4		—		—		4.4
Total	$	21.8	$	—	$	—	$	21.8

(in millions)			Unrealized		Unrealized
June 30, 201 6	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	1.5	$	—	$	—	$	1.5
Debt securities of U.S. government agencies		2.0		—		—		2.0
U.S. Treasury securities		7.0		—		—		7.0
Corporate notes		2.9		0.1		—		3.0
Certificates of deposit		7.3		—		—		7.3
Total	$	20.7	$	0.1	$	—	$	20.8

As of

September 30, 2016, the Company had no investments in an unrealized gain (loss) position. As of June 30, 2016, the Company had investments in an unrealized gain (loss) position below material disclosure thresholds in the table above. The Company has determined that the unrealized gains and losses on these investments are temporary in nature and expects the security to mature at its stated maturity principal. All available-for-sale securities held at September 30, 2016, will mature within a one year period.

The fair value of cash, accounts receivable, accounts payable and accrued liabilities approximate their carrying value because of the short-term nature of these financial instruments respectively, at

September 30

, 2016

and June 30, 2016

. The fair value of the Company’s short-term note payable, which is measured using Level 2 inputs, approximates book value, at

September 30

, 2016

and June 30, 2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 4 - Accrued and Other Current Liabilities

3 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

(4)	Accrued and Other Current Liabilities

Accrued expenses consist of the following (in millions):

	September 30 , 201 6		June 30, 201 6

Professional fees	$	0.6	$	0.1
Salary and benefits		0.3		0.6
Research and development expenses		4.6		2.2
Other accrued expenses		0.1		0.7
Total accrued expenses and other liabilities	$	5.6	$	3.6

Note 5 - Liabilities Related to Sale of Future Royalties

3 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Deferred Revenue Disclosure [Text Block]

(

)

Liabilities Related to Sale of Future Royalties

In April 2016, the Company sold certain royalty rights related to the approved product Inavir

, sold by Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in the Japanese market, for $20 million to HealthCare Royalty Partners III, L.P. (“HCRP”). Under the relevant accounting guidance, due to a limit on the amount of royalties that HCRP can earn under the arrangement, this transaction was accounted for as a liability that will be amortized using the interest method over the life of the arrangement. The Company has no obligation to pay any amounts to HCRP other than to pass through to HCRP its share of royalties as they are received from Daiichi Sankyo. In order to record the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received under the License Agreement with Daiichi Sankyo and the payments that will be passed through to HCRP over the life of the agreement. The sum of the pass through amounts less the net proceeds received will be recorded as non-cash interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records non-cash interest expense using an estimated effective interest rate. The Company will periodically assess the expected royalty payments, and to the extent such payments are greater or less than the initial estimate, the Company will adjust the amortization of the liability and interest rate. As a result of this accounting, even though the Company does not retain HCRP’s share of the royalties, it will continue to record non-cash revenue related to those royalties until the amount of the associated liability and related interest is fully amortized.

The following table shows the activity within the liability account during the three months ended September 30, 2016:

	in millions
Total Liability related to sale of future royalties, June 30, 2016	$	18.1
Non-cash royalty revenue paid to HCRP		(0.1	)
Non-cash interest expense recognized		0.4
Total Liability related to sale of future royalties, September 30, 2016	$	18.4

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Note 6 - Net Loss Per Share

3 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Earnings Per Share [Text Block]

(6)	Net Loss per share

Basic and diluted net loss per share has been computed based on net loss and the weighted-average number of common shares outstanding during the applicable period. For diluted net loss per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and unvested restricted stock units) are excluded from the calculation as their inclusion would be anti-dilutive. The Company has excluded all anti-dilutive share-based awards to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.

The following tables set forth the computation of historical basic and diluted net income (loss) per share.

	Three Months Ended September 30 ,
	201 6			201 5

Net income (loss) (in millions)	$	(10.0	)	$	(6.6	)
Weighted-average shares outstanding		38,640,487			38,624,227
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		38,640,487			38,624,227
Basic net income (loss) per share	$	(0.26	)	$	(0.17	)
Diluted net income (loss) income per share	$	(0.26	)	$	(0.17	)
Number of anti-dilutive share-based awards excluded from computation		5,806,900			4,394,607

Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements

3 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Collaborative Arrangement Disclosure [Text Block]

(7 )	Licenses, Royalty Collaborative and Contractual Arrangements

Royalty agreements

The Company entered into a royalty-bearing research and license agreement with GlaxoSmithKline (“GSK”) in 1990 for the development and commercialization of zanamivir, a neuraminidase inhibitor (“NI”) marketed by GSK as Relenza® to treat influenza. Under the terms of the agreement, the Company licensed zanamivir to GSK on an exclusive, worldwide basis and is entitled to receive royalty payments of 7% of GSK's annual net sales of Relenza

in the U.S., Europe, Japan and certain other countries as well as 10% of GSK's annual net sales of Relenza

in Australia, New Zealand, South Africa and Indonesia. Most of the Company’s Relenza

patents have expired and the only substantial remaining intellectual property related to the Relenza

patent portfolio is scheduled to expire in July 2019 in Japan. In the U.S., the Company has a pending patent application, No. 08/737,141, relating to inhalation treatment of influenza with Relenza

. In October 2016, the United States Court of Appeals for the Federal Circuit Decision Board upheld the United States Patent Office’s rejection of claims in the patent application. The Company is working with its partner GSK to evaluate possible next steps in the prosecution of this patent application. However, based on the most recent unsuccessful appeal, the Company believes it is unlikely that the U.S. patent claims will ever be issued and that the Company will not receive any further royalties on U.S. sales of the product.

The Company also generates royalty revenue from the sale of Inavir

(laninamivir octanoate or LANI) in Japan, pursuant to a collaboration and license agreement that the Company entered into with Daiichi Sankyo in 2009. In September 2010, Inavir

was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children. Under the agreement, the Company currently receives a 4% royalty on net sales of Inavir

in Japan and is eligible to earn sales milestone payments. Under the collaboration and license agreement, the Company and Daiichi Sankyo have cross-licensed the world-wide rights to develop and commercialize the related intellectual property, and have agreed to share equally in any royalties, license fees, or milestone or other payments received from any third party licenses outside of Japan. Patents on the composition of matter for LANI in Japan generally expire in 2024.

On April 22, 2016, the Company entered into a Royalty Interest Acquisition Agreement (“Agreement”) with HCRP. Under the Agreement, HCRP made a $20 million cash payment to the Company in consideration for acquiring from the Sellers certain royalty rights (“Royalty Rights”) related to the approved product Inavir

in the Japanese market. The Royalty Rights were obtained pursuant to the collaboration and license agreements (the “License Agreement”) and a commercialization agreement that the Company entered into with Daiichi Sankyo Company, Limited.

The following tables summarize the key components of the Company’s revenues (in millions):

	Three Months Ended September 30,
	2016		2015
	(in millions)
Royalty revenue – Relenza ®	$	0.1	$	1.7
Total revenue	$	0.1	$	1.7

Collaborative and contract arrangements

In July 2016, the Company entered into an exclusive, worldwide license for RSV replication inhibitors intellectual property with Georgia State University Research Foundation (“GSURF”) in exchange for an upfront fee, future milestone payments and royalties on future net sales of any products that utilize the underlying RSV intellectual property. The Company has an obligation to make a minimum payment of $10,000 to GSURF annually until the license agreement expires or is terminated. The Company also entered into a two year sponsored research agreement with GSURF for annual sponsored research payments.

In connection with the Company’s BTA585 clinical trial, a Clinical Research Organization (“CRO”), engaged by the Company to provide certain services for this trial, notified the Company of its intent to explore additional compensation in an amount up to $1.6 million, due to a previous delay in the trial. The Company is currently reviewing the facts of the notice and due to the early stages of the matter described above, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from these matters. As such, the Company is not currently able to estimate the impact of the potential additional expense on its financial position or results of operations.

Note 8 - Share-based Compensation

3 Months Ended

Sep. 30, 2016

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(

)

Share-based Compensation

For the three month periods ended September 30, 2016 and 2015, the Company recorded share-based compensation expense related to grants from equity incentive plans of $0.4 million and $0.6 million, respectively. No income tax benefit was recognized in the statements of operations and no share-based compensation expense was capitalized as part of any assets for the three month periods ended September 30, 2016 and 2015.

Stock Options

The fair value of each stock option award was estimated at its respective date of grant using the Black-Scholes method with the following assumptions:

	Three Months Ended September 3 0 ,
	201 6			201 5
Weighted-average risk-free interest rate		1.10	%		1.50	%
Dividend yield		—			—
Expected weighted-average volatility		.76			.75
Expected weighted-average life of options (years)		6.0			4.0
Weighted-average fair value of options granted	$	0.87		$	1.35

The risk-free rate interest rate is based on the expected life of the option and the corresponding U.S. Treasury bond, which in most cases is the U.S. five year Treasury bond. The expected term of stock options granted is derived from actual and expected option behavior and represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise patterns and future employee terminations to determine expected life and forfeitures. Expected volatility is based on the historical volatility of the Company’s publicly traded common stock.

A summary of the Company’s outstanding stock option activity for the three months ended September 30, 2016 is as follows:

	Number of Stock Options			Weighted Average Exercise Price Per Option		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value($000)
						(In Years)
Outstanding at June 30, 2016		4,751,423		$	4.07				-
Granted		1,310,000			1.33
Exercised		—			—
Forfeited or expired		(254,523	)		2.59
Outstanding at September 30, 2016		5,806,900		$	3.52		7.4	$	-

The total intrinsic value of stock options exercised during the three month period ended September 30, 2016 was zero, and no cash proceeds were received by the Company. Further, no actual tax benefits were realized, as the Company currently records a full valuation allowance for all tax benefits due to uncertainties with respect to its ability to generate sufficient taxable income in the future.

The following tables summarize information relating to outstanding and exercisable options as of September 30, 2016:

				September 30 , 2016
				Outstanding Weighted Average							Exercisable
Exercise Prices				Number of Stock Options		Remaining Contractual Life		Weighted Average Exercise Price		Number of Stock Options		Weighted Average Exercise Price
						(In Years)
$	1.30	—	1.40		1,514,167		9.82	$	1.34		9,167	$	1.37
$	1.50	—	2.45		1,617,547		8.02		2.26		491,460		2.37
$	2.47	—	4.07		2,274,000		5.79		3.29		1,587,290		3.61
$	4.15	—	39.60		401,186		4.89		18.08		308,686		22.02
					5,806,900		7.40	$	3.52		2,396,603		5.72

Restricted Stock Units and Market Stock Units (MSUs).

A summary of the Company’s outstanding restricted stock and market stock unit (MSU) activity for the three months ended September 30, 2016 is as follows:

	Shares			Weighted Average Grant Date Fair Value
Balance at June 30, 2016		49,206		$	4.00
Awarded		-			-
Released		-			-
Forfeited		(4,375	)		4.00
Balance at September 30, 2016		44,831		$	4.00

As of September 30, 2016 there was $2.9 million of unrecognized share-based compensation expense related to all unvested share-based awards. Unrecognized stock-based compensation expense for equity awards will be adjusted for future changes in estimated forfeitures. This balance is expected to be recognized over a weighted-average period of approximately 2.1 years.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. All material adjustments considered necessary for a fair presentation have been included. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (“SEC”). Except as disclosed herein, there has been no material change in the information disclosed in the notes to the condensed consolidated financial statements included in the Company’s Annual Report on Form 10-K that was filed with the SEC on September 13, 2016. The unaudited interim condensed consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All inter-company transactions and balances are eliminated in consolidation. Operating results for the three months ended September 30, 2016 are not necessarily indicative of those in future quarters or the annual results that may be expected for the Company’s fiscal year ending June 30, 2017. For a more complete discussion of the Company’s significant accounting policies and other information, this report should be read in conjunction with the consolidated financial statements for the fiscal year ended June 30, 2016 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on September 13, 2016. The Company’s significant accounting policies have not changed since June 30, 2016.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Standards In May 2014, the FASB issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2017. Accordingly, the Company will adopt this guidance on July 1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements. In August 2014, the FASB issued authoritative accounting guidance related to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. This guidance is effective for annual reporting ending after December 15, 2016, and for annual periods and interim periods thereafter with early application permitted. Accordingly, the standard is effective for the Company on June 30, 2017. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements. In January 2016, the FASB issued guidance related to financial instruments - overall recognition and measurement of financial assets and financial liabilities. The guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for public companies for interim and annual periods beginning after December 15, 2017. Accordingly, the standard is effective for the Company on July 1, 2018. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements. In February 2016, the FASB issued new guidance on leases. This guidance replaces the prior lease accounting guidance in its entirety. The underlying principle of the new standard is the recognition of lease assets and lease liabilities by lessees for substantially all leases, with an exception for leases with terms of less than twelve months. The standard also requires additional quantitative and qualitative disclosures. The guidance is effective for interim and annual reporting periods beginning after December 15, 2018, and early adoption is permitted. The standard requires a modified retrospective approach, which includes several optional practical expedients. Accordingly, the standard is effective for the Company on July 1, 2019. The Company is currently evaluating the impact that this guidance will have on the consolidated financial statements.

Note 3 - Fair Value Measurements (Tables)

3 Months Ended

Sep. 30, 2016

Notes Tables

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

(in millions)			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
September 30 , 201 6	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	9.4	$	9.4	$	—	$	—
Short-term investments available-for-sale		12.4		6.0		6.4		—
Total	$	21.8	$	15.4	$	6.4	$	—

(in millions)			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
June 30, 201 6	Total		(Level 1)		(Level 2)		(Level 3)
Cash equivalents	$	1.5	$	1.5	$	—	$	—
Short-term investments available-for-sale	19.3			10.0		9.3		—
Total	$	20.8	$	11.5	$	9.3	$	—

Unrealized Gain (Loss) on Investments [Table Text Block]

(in millions)			Unrealized		Unrealized
September 30, 2016	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	9.4	$	—	$	—	$	9.4
Debt securities of U.S. government agencies		2.0		—		—		2.0
U.S. Treasury securities		4.0		—		—		4.0
Corporate notes		2.0		—		—		2.0
Certificates of deposit		4.4		—		—		4.4
Total	$	21.8	$	—	$	—	$	21.8

(in millions)			Unrealized		Unrealized
June 30, 201 6	At Cost		Gains		(Losses)		At Fair Value
Money market funds	$	1.5	$	—	$	—	$	1.5
Debt securities of U.S. government agencies		2.0		—		—		2.0
U.S. Treasury securities		7.0		—		—		7.0
Corporate notes		2.9		0.1		—		3.0
Certificates of deposit		7.3		—		—		7.3
Total	$	20.7	$	0.1	$	—	$	20.8

Note 4 - Accrued and Other Current Liabilities (Tables)

3 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	September 30 , 201 6		June 30, 201 6

Professional fees	$	0.6	$	0.1
Salary and benefits		0.3		0.6
Research and development expenses		4.6		2.2
Other accrued expenses		0.1		0.7
Total accrued expenses and other liabilities	$	5.6	$	3.6

Note 5 - Liabilities Related to Sale of Future Royalties (Tables)

3 Months Ended

Sep. 30, 2016

Notes Tables

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

	in millions
Total Liability related to sale of future royalties, June 30, 2016	$	18.1
Non-cash royalty revenue paid to HCRP		(0.1	)
Non-cash interest expense recognized		0.4
Total Liability related to sale of future royalties, September 30, 2016	$	18.4

Note 6 - Net Loss Per Share (Tables)

3 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30 ,
	201 6			201 5

Net income (loss) (in millions)	$	(10.0	)	$	(6.6	)
Weighted-average shares outstanding		38,640,487			38,624,227
Dilutive effect of restricted stock and stock options		-			-
Shares used to compute diluted earnings per share		38,640,487			38,624,227
Basic net income (loss) per share	$	(0.26	)	$	(0.17	)
Diluted net income (loss) income per share	$	(0.26	)	$	(0.17	)
Number of anti-dilutive share-based awards excluded from computation		5,806,900			4,394,607

Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Tables)

3 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended September 30,
	2016		2015
	(in millions)
Royalty revenue – Relenza ®	$	0.1	$	1.7
Total revenue	$	0.1	$	1.7

Note 8 - Share-based Compensation (Tables)

3 Months Ended

Sep. 30, 2016

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Three Months Ended September 3 0 ,
	201 6			201 5
Weighted-average risk-free interest rate		1.10	%		1.50	%
Dividend yield		—			—
Expected weighted-average volatility		.76			.75
Expected weighted-average life of options (years)		6.0			4.0
Weighted-average fair value of options granted	$	0.87		$	1.35

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Stock Options			Weighted Average Exercise Price Per Option		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value($000)
						(In Years)
Outstanding at June 30, 2016		4,751,423		$	4.07				-
Granted		1,310,000			1.33
Exercised		—			—
Forfeited or expired		(254,523	)		2.59
Outstanding at September 30, 2016		5,806,900		$	3.52		7.4	$	-

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

				September 30 , 2016
				Outstanding Weighted Average							Exercisable
Exercise Prices				Number of Stock Options		Remaining Contractual Life		Weighted Average Exercise Price		Number of Stock Options		Weighted Average Exercise Price
						(In Years)
$	1.30	—	1.40		1,514,167		9.82	$	1.34		9,167	$	1.37
$	1.50	—	2.45		1,617,547		8.02		2.26		491,460		2.37
$	2.47	—	4.07		2,274,000		5.79		3.29		1,587,290		3.61
$	4.15	—	39.60		401,186		4.89		18.08		308,686		22.02
					5,806,900		7.40	$	3.52		2,396,603		5.72

Schedule of Nonvested Performance-based Units Activity [Table Text Block]

	Shares			Weighted Average Grant Date Fair Value
Balance at June 30, 2016		49,206		$	4.00
Awarded		-			-
Released		-			-
Forfeited		(4,375	)		4.00
Balance at September 30, 2016		44,831		$	4.00

Note 3 - Fair Value Measurements (Details Textual)	3 Months Ended
Note 3 - Fair Value Measurements (Details Textual)	Sep. 30, 2016
Available-for-Sale Securities, Maturity Period	1 year

Note 3 - Fair Value Measurements - Summary of Investments (Details) - USD ($) $ in Millions	Sep. 30, 2016	Jun. 30, 2015
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Available for Sale Securities - Current	$ 9.4	$ 1.5
Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Available for Sale Securities - Current
Money Market Funds [Member] \| Fair Value, Inputs, Level 3 [Member]
Available for Sale Securities - Current
Money Market Funds [Member]
Available for Sale Securities - Current	9.4	1.5
Short-term Investments [Member] \| Fair Value, Inputs, Level 1 [Member]
Available for Sale Securities - Current	6.0	10.0
Short-term Investments [Member] \| Fair Value, Inputs, Level 2 [Member]
Available for Sale Securities - Current	6.4	9.3
Short-term Investments [Member] \| Fair Value, Inputs, Level 3 [Member]
Available for Sale Securities - Current
Short-term Investments [Member]
Available for Sale Securities - Current	12.4	19.3
Fair Value, Inputs, Level 1 [Member]
Total	15.4	11.5
Fair Value, Inputs, Level 2 [Member]
Total	6.4	9.3
Fair Value, Inputs, Level 3 [Member]
Total
Available for Sale Securities - Current	21.8	20.8
Total	$ 21.8	$ 20.8

Note 3 - Fair Value Measurements - Unrealized Gain (Loss) on Investments (Details) - USD ($) $ in Millions	Sep. 30, 2016	Jun. 30, 2015
Money Market Funds [Member]
At Cost	$ 9.4	$ 1.5
Unrealized Gains
Unrealized (Losses)
Fair Value	9.4	1.5
US Government Agencies Debt Securities [Member]
At Cost	2.0	2.0
Unrealized Gains
Unrealized (Losses)
Fair Value	2.0	2.0
US Treasury Securities [Member]
At Cost	4.0	7.0
Unrealized Gains
Unrealized (Losses)
Fair Value	4.0	7.0
Corporate Note Securities [Member]
At Cost	2.0	2.9
Unrealized Gains		0.1
Unrealized (Losses)
Fair Value	2.0	3.0
Certificates of Deposit [Member]
At Cost	4.4	7.3
Unrealized Gains
Unrealized (Losses)
Fair Value	4.4	7.3
At Cost	21.8	20.7
Unrealized Gains		0.1
Unrealized (Losses)
Fair Value	$ 21.8	$ 20.8

Note 4 - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2016	Jun. 30, 2016
Professional fees	$ 0.6	$ 0.1
Salary and benefits	0.3	0.6
Research and development expenses	4.6	2.2
Other accrued expenses	0.1	0.7
Total accrued expenses and other liabilities	$ 5.6	$ 3.6

Note 5 - Liabilities Related to Sale of Future Royalties (Details Textual) $ in Millions	1 Months Ended
	Apr. 30, 2016 USD ($)
HealthCare Royalty Partners III, L.P. [Member] \| Royalty Arrangement [Member]
Deferred Revenue, Additions	$ 20

Note 5 - Liabilities Related to Sale of Future Royalties - Deferred Revenue Activity (Details) - Royalty Arrangement [Member] - HealthCare Royalty Partners III, L.P. [Member] $ in Millions	3 Months Ended
	Sep. 30, 2016 USD ($)
Total Liability related to sale of future royalties, June 30, 2016	$ 18.1
Non-cash royalty revenue paid to HCRP	(0.1)
Non-cash interest expense recognized	0.4
Total Liability related to sale of future royalties, September 30, 2016	$ 18.4

Note 6 - Net Loss Per Share - Computation of Historical Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Net loss	$ (10.0)	$ (6.6)
Weighted-average shares outstanding (in shares)	38,640,487	38,624,227
Shares used to compute diluted earnings per share (in shares)	38,640,487	38,624,227
Basic net income (loss) per share (in dollars per share)	$ (0.26)	$ (0.17)
Diluted net income (loss) income per share (in dollars per share)	$ (0.26)	$ (0.17)
Number of anti-dilutive share-based awards excluded from computation (in shares)	5,806,900	4,394,607

Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements (Details Textual) - USD ($)		3 Months Ended
	Apr. 22, 2016	Sep. 30, 2016
United States, Europe, Japan, And Other Countries [Member] \| GSK [Member]
Royalty Payment Percentage		7.00%
Australia, New Zealand, South Africa, and Indonesia [Member] \| GSK [Member]
Royalty Payment Percentage		10.00%
Japan [Member] \| Daiichi Sankyo [Member]
Royalty Payment Percentage		4.00%
HealthCare Royalty Partners III, L.P. [Member]
Proceeds From Sale of Royalty Rights, Gross	$ 20,000,000
Georgia State University Research Foundation (GSURF) [Member]
Collaborative Arrangement, Annual Minimum Payment		$ 10,000
Collaborative Agreement, Number of Years of Sponsored Research Agreement		2 years
Clinical Research Organization [Member]
Collaborative Arrangement, Potential Additional Compensation		$ 1,600,000

Note 7 - Licenses, Royalty, Collaborative and Contractual Arrangements - Components of Revenues from Royalties, Collaborative and Contractual Agreements (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Relenza [Member]
Royalty revenue and milestones	$ 0.1	$ 1.7
Royalty revenue and milestones	0.1	1.7
Total revenue	$ 0.1	$ 1.7

Note 8 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
The 2007 Omnibus Equity and Incentive Plan [Member]
Allocated Share-based Compensation Expense	$ 400,000	$ 600,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	0	0
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 2,900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 36 days

Note 8 - Share-based Compensation - Fair Value Assumptions (Details) - $ / shares	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Weighted-average risk-free interest rate	1.10%	1.50%
Dividend yield
Expected weighted-average volatility	0.76%	0.75%
Expected weighted-average life of options (years)	6 years	4 years
Weighted-average fair value of options granted (in dollars per share)	$ 0.87	$ 1.35

Note 8 - Share-based Compensation - Stock Option Activity (Details)	3 Months Ended
	Sep. 30, 2016 $ / shares shares
Outstanding (in shares) \| shares	4,751,423
Outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 4.07
Granted (in shares) \| shares	1,310,000
Granted, weighted average exercise price (in dollars per share) \| $ / shares	$ 1.33
Exercised (in shares) \| shares
Exercised, weighted average exercise price (in dollars per share) \| $ / shares
Forfeited or expired (in shares) \| shares	(254,523)
Forfeited or expired, weighted average exercise price (in dollars per share) \| $ / shares	$ 2.59
Outstanding (in shares) \| shares	5,806,900
Outstanding, weighted average exercise price (in dollars per share) \| $ / shares	$ 3.52
Outstanding, weighted-average remaining contractual term	7 years 146 days

Note 8 - Share-based Compensation - Exercise Price Range Relating to Outstanding and Exercisable Options (Details)	3 Months Ended
	Sep. 30, 2016 $ / shares shares
Range One [Member]
Exercise price range, lower limit (in dollars per share)	$ 1.30
Exercise price range, upper limit (in dollars per share)	$ 1.40
Outstanding Weighted Average Number of Stock Options (in shares) \| shares	1,514,167
Outstanding Weighted Average Remaining Contractual Life	9 years 299 days
Weighted Average Exercise Price (in dollars per share)	$ 1.34
Exercisable Number of Stock Options (in shares) \| shares	9,167
Exercisable Weighted Average Exercise Price (in dollars per share)	$ 1.37
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	1.50
Exercise price range, upper limit (in dollars per share)	$ 2.45
Outstanding Weighted Average Number of Stock Options (in shares) \| shares	1,617,547
Outstanding Weighted Average Remaining Contractual Life	8 years 7 days
Weighted Average Exercise Price (in dollars per share)	$ 2.26
Exercisable Number of Stock Options (in shares) \| shares	491,460
Exercisable Weighted Average Exercise Price (in dollars per share)	$ 2.37
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	2.47
Exercise price range, upper limit (in dollars per share)	$ 4.07
Outstanding Weighted Average Number of Stock Options (in shares) \| shares	2,274,000
Outstanding Weighted Average Remaining Contractual Life	5 years 288 days
Weighted Average Exercise Price (in dollars per share)	$ 3.29
Exercisable Number of Stock Options (in shares) \| shares	1,587,290
Exercisable Weighted Average Exercise Price (in dollars per share)	$ 3.61
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	4.15
Exercise price range, upper limit (in dollars per share)	$ 39.60
Outstanding Weighted Average Number of Stock Options (in shares) \| shares	401,186
Outstanding Weighted Average Remaining Contractual Life	4 years 324 days
Weighted Average Exercise Price (in dollars per share)	$ 18.08
Exercisable Number of Stock Options (in shares) \| shares	308,686
Exercisable Weighted Average Exercise Price (in dollars per share)	$ 22.02

Note 8 - Share-based Compensation - Summary of Restricted Stock Units and MSU Activity (Details) - Restricted Stock and Market Stock Units [Member]	3 Months Ended
	Sep. 30, 2016 $ / shares shares
Balance (in shares)	49,206
Balance, weighted average grant date fair value (in dollars per share) \| $ / shares	$ 4
Awarded (in shares)
Released (in shares)
Forfeited (in shares)	(4,375)
Forfeited, weighted average grant date fair value (in dollars per share) \| $ / shares	$ 4
Balance (in shares)	44,831
Balance, weighted average grant date fair value (in dollars per share) \| $ / shares	$ 4